Pfizer Announces Conclusion of Consent Solicitation For $22.5 Million of Debt

Pfizer Announces Conclusion of Consent Solicitation For $22.5 Million of Debt

Pfizer Inc.

Pfizer Inc. (NYSE: PFE) today announced the results of its solicitation of consents to amend certain provisions of the indentures with respect to the following outstanding debt securities of its wholly-owned subsidiary Pharmacia Corporation:

Based on information provided by D.F. King & Co., Inc., the information and tabulation agent for the consent solicitation, as of 5:00 p.m., New York City time, on Monday, August 27, 2012, the required consents from holders of the $20,000,000 outstanding aggregate principal amount of 6.47% Notes due 2018, CUSIP No. 61167HBK8, and outstanding aggregate principal amount of $2,507,000 8.70% Debentures due 2021, CUSIP No. 71713UAR3 had not been received. Adoption of the proposed amendments required consent of holders of at least 66/% in principal amount of each series of debt securities.

Because the required consents were not received, Pfizer will not make any consent payment in accordance with the terms of the consent solicitation.

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at .

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.